A case of a chronic lung berylliosis in a 20-year-old woman with a 20-weeks pregnancy is described. The diagnosis is established on the basis of morphological features: fibrosing alveolitis with numerous lympho-histiocytic granulomas containing conchoidal bodies and the lung tissue chemical analysis showing the presence of beryllium (2.71 X 10(-6) g/organ). Morphology of the lungs is described in detail.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Sarcoidosis in Beryllium Exposed Workers: A Case-Case Study.
Am J Ind Med
January 2025
Division of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Health, Denver, Colorado, USA.
Background: Despite the utility of the beryllium lymphocyte proliferation test (BeLPT), distinguishing sarcoidosis, a disease of unknown etiology, from chronic beryllium disease (CBD), has long posed a diagnostic challenge. It is unclear if beryllium-exposed sarcoidosis cases (Be-exp-Sarc) are clinically distinct from CBD, or are misdiagnosed cases of CBD.
Methods: We performed a case-case study of 40 beryllium-exposed individuals diagnosed with Be-exp-Sarc compared to 40 frequency-matched CBD cases.
Chronic berylliosis disease: uncommon pulmonary granulomas beyond sarcoidosis.
Thorax
October 2024
Thoracic Surgery, SLK-Lungenklinik Lowenstein, Lowenstein, Germany.
Multisystemic Beryllium Disease: An Exceptional Case Revealed by a Urinary Tract Granulomatosis.
Int J Mol Sci
July 2024
Department of Nephrology and Dialysis, Brugmann University Hospital, Université libre de Bruxelles, 1020 Bruxelles, Belgium.
Article Synopsis
- Chronic beryllium disease (CBD) is an interstitial lung condition caused by inhaling beryllium particles, and it can often be confused with sarcoidosis but has distinct characteristics and complications.
- A case involving a 60-year-old man revealed multi-organ involvement, with his kidney issues stemming from CBD rather than typical pulmonary symptoms, which were relatively mild.
- The report emphasizes the need for healthcare providers to consider CBD as a potential diagnosis in patients exhibiting granulomatous diseases, especially when they present with related respiratory issues, despite the absence of classical lung symptoms.
Mortality Among Individuals Diagnosed With Chronic Beryllium Disease and Beryllium Sensitization.
J Occup Environ Med
March 2024
From the Division of Occupational and Environmental Medicine, Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, MI (H.T., L.W., K.D.R.); and Materion Brush, Inc, Elmore, OH (C.D.).
Objective: The aim of the study is to investigate the cause of death among individuals diagnosed with chronic beryllium disease (CBD) or beryllium sensitization (BeS).
Methods: Vital status, cause of death, and standardized mortality ratios for the underlying cause of death were determined for a cohort of 354 individuals with CBD and 290 individuals with BeS.
Results: Among 216 deceased individuals, 153 had CBD and 63 had BeS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!